Source - RNS
RNS Number : 5034K
Venn Life Sciences Holdings PLC
22 September 2016
 

22 September 2016

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

 

Appointment of Non-Executive Director

 

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Mary Sheahan as a Non-Executive Director ('NED') to the Board with immediate effect.

 

Mary Blake Sheahan, aged  44,  is a dedicated senior leader with over 20 years' experience, at Executive Committee level of a multinational publicly listed biopharmaceutical company. Mary's most recent role was as Senior Vice President of Global Integration and Country Manager for Ireland with Perrigo Company plc, a NYSE-listed, $13 billion market cap leading global healthcare supplier. In this role, she was responsible for the successful integration of a $4.5bn acquisition of a leading European OTC Healthcare Company with operations in 35 countries.

 

Prior to this, Mary was Executive Vice President and Group Head of HR, IT, Facilities & Portfolio Assessment Management at Elan Corporation plc prior to its merger with Perrigo in 2013.  Mary is a qualified chartered accountant having trained with KPMG.

 

Tony Richardson, Chief Executive Officer of Venn said: "Mary will be a great addition to the Board  in a time of great progress and change at Venn. She has a proven track record of setting direction, strategic decision-making and delivering results in complex and challenging situations, across a range of disciplines including finance, strategy and commercial functions. She will add considerable value to our team.

 

Mary has confirmed that there are no other items requiring disclosure in accordance with Schedule 2(g)(iii) to (viii) of the AIM rules and the ESM Rules.

 

Current directorships or partnerships

Directorships or partnerships in the last five years



Madiba Consulting Limited

Elan Science Three Limited

 

Prothena Corporation, plc

Perrigo Holdings Limited

Perrigo Corporation Limited

Janssen Alzheimer Immunotherapy Unlimited

Perrigo Finance plc



  

Mary does not hold any interests in ordinary shares of Venn.

 

Enquiries:

 

 

Venn Life Sciences Holdings Plc


Allan Wood, Chairman

Tel: +447185325898

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341



Davy (Nominated Adviser, ESM Adviser and Joint Broker)


Fergal Meegan / Matthew de Vere White (Corporate Finance)

Tel: +353 1 679 6363

Orla Bolger (Corporate Broking)




Hybridan LLP (Co-Broker)


Claire Louise Noyce

 Tel: +44(0) 20 3764 2341 



Walbrook PR Ltd

          Tel: +44(0)20 7933 8787 or [email protected]

Paul McManus   

Mob: +44(0) 7980 541 893

Lianne Cawthorne

Mob: +44(0) 7584 391 303

 

 

About Venn Life Sciences:

 

 

Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKFLFLQKFFBBD

Related Charts

Venn Life Sciences Holdings (VENN)

0.00p (0.00%)
delayed 18:15PM